ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Pre-Transplant Intra-Arterial Liver Directed Therapy Does Not Increase the Risk of Hepatic Arterial Misadventures in Liver Transplantation.

J. Kallini,2 A. Gabr,2 R. Salem,2 R. Lewandowski,2 T. Baker.1

1Comprehensive Transplant Center, Northwestern University, Chicago, IL
2Division of Interventional Oncology, Northwestern University, Chicago, IL.

Meeting: 2016 American Transplant Congress

Abstract number: A197

Keywords: Adverse effects, Hepatic artery, Hepatocellular carcinoma, Liver transplantation

Session Information

Session Name: Poster Session A: Liver - Hepatocellular Carcinoma and Cholangiocarcinoma Malignancies

Session Type: Poster Session

Date: Saturday, June 11, 2016

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Halls C&D

Background: Pretransplant liver directed therapy has emerged as standard of care for patients with end stage liver disease complicated by unresectable hepatocellular cancer. The aim of this study was todetermine whether pre-transplant intra-arterial liver directed therapy (LRT) for hepatocellular carcinoma (HCC) increases the risk of hepatic arterial misadventures (the necessity of a conduit or hepatic artery thrombosis) associated with liver transplant (LT).

Methods: 175 HCC patients underwent LRT with either trans-arterial chemoembolization (TACE) or trans-arterial radioembolization (TARE) with yttrium-90 (Y90) prior to LT between 2003 and 2013 (TACE, n = 82; TARE, n = 93). LT candidates were considered for LRT if they had unresectable HCC (determined by a multidisciplinary tumor board) and bilirubin < 3.0 mg/d. Patients with portal vein thrombosis, extrahepatic metastases, and receiving both TACE and TARE were excluded. A matched control cohort of 159 HCC LT patients who did not have pre-transplant intra-arterial LRT was selected. Diseased/injured recipient hepatic arterial (HA) vasculature was noted to be present if (1) the operative report noted poor-quality recipient vasculature necessitating conduit reconstruction and/or (2) if HAT developed up to two weeks post-operatively.

Results: Among the 175 LRT patients (TACE, n=82; TARE, n=93), 8 required conduits (TACE, n=6; TARE, n=2) and 3 developed HAT (TACE, n=2; TARE, n=1). Of the 159 controls, 7 needed conduits (4%) and 3 developed HAT (2%). Two-tailed z-test between the LRT and the control group reveals a Z-Score of -0.0014 and p-value of 1 (no significant difference). Importantly, when TACE was compared to TARE, neither group demonstrated a higher incidence of arterial injury (Z-Score = 1.78, p-value = 0.075).

Conclusion: Although aggressive pretransplant TARE and TACE are both utilized in most liver transplant centers in HCC patients, neither appears to increase the risk of hepatic arterial misadventure during LT when compared to our control group. These encouraging results lay the foundation for future studies to determine which LRT offers optimal tumor control without concern for collateral arterial injury.

CITATION INFORMATION: Kallini J, Gabr A, Salem R, Lewandowski R, Baker T. Pre-Transplant Intra-Arterial Liver Directed Therapy Does Not Increase the Risk of Hepatic Arterial Misadventures in Liver Transplantation. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Kallini J, Gabr A, Salem R, Lewandowski R, Baker T. Pre-Transplant Intra-Arterial Liver Directed Therapy Does Not Increase the Risk of Hepatic Arterial Misadventures in Liver Transplantation. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/pre-transplant-intra-arterial-liver-directed-therapy-does-not-increase-the-risk-of-hepatic-arterial-misadventures-in-liver-transplantation/. Accessed May 30, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences